Current through 82nd (2023) Legislative Session Chapter 535 and 34th (2023) Special Session Chapter 1 and 35th (2023) Special Session Chapter 1
Section 639.2623 - Authority; requirements to enter into collaborative practice agreement; duties of pharmacist; patient consent required; conditions and limitations1. A pharmacist who has entered into a valid collaborative practice agreement may engage in the collaborative practice of pharmacy or collaborative drug therapy management at any location in this State.2. To enter into a collaborative practice agreement, a practitioner must: (a) Be licensed in good standing to practice his or her profession in this State; and(b) Agree to obtain the informed, written consent from a patient who is referred by the practitioner to a pharmacist pursuant to a collaborative practice agreement for collaborative drug therapy management. The provisions of this paragraph must not be construed to require a patient to obtain a referral from a practitioner before a pharmacist may engage in the collaborative practice of pharmacy or collaborative drug therapy management.3. A practitioner shall not enter into a collaborative practice agreement with a collaborating pharmacist if the geographic distance between the practitioner and the collaborating pharmacist prevents or limits effective collaboration in the delivery of care or treatment to patients.4. Except as otherwise provided in this subsection, a practitioner shall not enter a collaborative practice agreement that includes diagnosis or initiating treatment unless the practitioner actively practices his or her profession in this State or provides those services using telehealth. The Board may grant a written request for an exemption from the requirements of this subsection for good cause shown.5. A collaborative practice agreement must not grant a pharmacist the authority to engage in an activity that is outside the scope of the current practice of the practitioner. 6. A pharmacist who engages in the collaborative practice of pharmacy shall:(a) Except as otherwise provided in paragraph (b), document any treatment or care provided to a patient pursuant to a collaborative practice agreement after providing such treatment or care in the medical record of the patient, on the chart of the patient or in a separate log book;(b) Document in the medical record of the patient, on the chart of the patient or in a separate log book any decision or action concerning the management of drug therapy pursuant to a collaborative practice agreement after making such a decision or taking such an action;(c) Maintain all records concerning the care or treatment provided to a patient pursuant to a collaborative practice agreement in written or electronic form for at least 7 years;(d) Comply with all provisions of the Health Insurance Portability and Accountability Act of 1996, Public Law 104-191, the regulations adopted pursuant thereto, and all other federal and state laws and regulations concerning the privacy of information regarding health care; and(e) Provide a patient with written notification of: (1) Any test administered by the pharmacist and the results of such a test;(2) The name of any drug or prescription filled and dispensed by the pharmacist to the patient; and(3) The contact information of the pharmacist.7. A pharmacist shall obtain the informed, written consent of a patient before engaging in the collaborative practice of pharmacy on behalf of the patient. Such written consent must include, without limitation, a statement that the pharmacist: (a) May initiate, modify or discontinue the medication of the patient pursuant to a collaborative practice agreement; and(b) Is not a physician, osteopathic physician, advanced practice registered nurse or physician assistant.8. A pharmacy must not require a registered pharmacist, as a condition of employment, to enter into a collaborative practice agreement.Added to NRS by 2017, 2519; A 2021, 1660Amended by 2021, Ch. 290,§2, eff. 10/1/2021.Added by 2017, Ch. 386,§4, eff. 7/1/2017.